Phase III Acne Drug Trial Begins in Aurora to Support NDA Submission
1 report, 1 independent
Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A pivotal Phase III clinical trial of denifanstat (ASC40) began in Aurora, where the first patient was dosed. The trial is designed to support a potential U.S. New Drug Application (NDA) submission. Previous Phase III trials showed denifanstat was significantly more effective than FDA-approved treatments like sarecycline and doxycycline.
From manilatimes.net
Why it matters
The drug aims to address a significant unmet need for moderate to severe acne among approximately 10 million Americans. If approved by the FDA, the treatment could enter the market, potentially altering the demand and pricing within the dermatology pharmaceutical sector.
From manilatimes.net
Who's involved
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
Related events
- A company is seeking definitive data for a pre-NDA meeting with the FDA in Raleigh.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA communicated eligibility for accelerated approval for ProKidney Corp., which plans to present study results at ASN.
- FDA approval enables commercial availability for a product associated with Indianapolis.